A Feline‐Specific Anti‐Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease–Associated Pain: A Pilot Proof of Concept Study
Background Neutralizing antibodies against nerve growth factor (NGF) are analgesic in rodent models, naturally occurring degenerative joint disease (DJD) pain in dogs, and chronic pain in humans. Objectives To evaluate the efficacy of a fully felinized anti‐NGF antibody (NV‐02) for the treatment of...
Gespeichert in:
| Veröffentlicht in: | Journal of veterinary internal medicine 2016-07, Vol.30 (4), p.1138-1148 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1148 |
|---|---|
| container_issue | 4 |
| container_start_page | 1138 |
| container_title | Journal of veterinary internal medicine |
| container_volume | 30 |
| creator | Gruen, M.E. Thomson, A.E. Griffith, E.H. Paradise, H. Gearing, D.P. Lascelles, B.D.X. |
| description | Background
Neutralizing antibodies against nerve growth factor (NGF) are analgesic in rodent models, naturally occurring degenerative joint disease (DJD) pain in dogs, and chronic pain in humans.
Objectives
To evaluate the efficacy of a fully felinized anti‐NGF antibody (NV‐02) for the treatment of DJD pain and mobility impairment in cats.
Animals
Thirty‐four client‐owned cats with DJD‐associated pain and mobility impairment.
Methods
In a placebo‐controlled, pilot, masked clinical study, cats were randomized to a single treatment with NV‐02 (0.4 mg/kg SC [n = 11] or 0.8 mg/kg SC [n = 12]) or placebo (saline, SC [n = 11]). Activity was measured objectively. Additionally, owners completed clinical metrology instruments (client‐specific outcome measures [CSOM] and feline musculoskeletal pain index [FMPI]) on days 0 (screening), 14 (baseline), 35, 56, and 77. A repeated‐measures model was used to evaluate the objective activity data.
Results
NV‐02 significantly increased objectively measured activity overall (P = .017) and at 2 (P = .035), 3 (P = .007), 4 (P = .006), 5 (P = .007), and 6 (P = .017) weeks after treatment. CSOM scores (P = .035) and pain (P = .024) showed a significant effect of treatment 3 weeks after administration. In the treatment group, 83% of the owners correctly identified the treatment administered compared with 45% of owners in the placebo group (P = .013). No treatment‐related adverse effects were identified.
Conclusions
These pilot data demonstrate a 6‐week duration positive analgesic effect of this fully felinized anti‐NGF antibody in cats suffering from DJD‐associated pain. |
| doi_str_mv | 10.1111/jvim.13972 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5153962</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1846311750</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5642-ba0f571b1d0a16724e553c54e72528db0014734f474602d9c42f3561a65415b13</originalsourceid><addsrcrecordid>eNqNkt1qFDEYhoModl098QIkhyJMze_MjgfCsHXrllYXqp6GTOabNmVmsk2yu8yZlyB4Cd6ZV2LarUVPxBAI4Xvy5O9F6DklhzS111db2x9SXhbsAZrQkpcZzYv8IZqQWUmzPBfkAD0J4YoQJqUsHqMDVnAuJBET9KPCC-jsAD-_fjtfg7GtNbgaok3zD-C3gI-928VLvNAmOn9bql0z4mW_9m4LAZ-52nY2jtgOeK5jwDub8CO4gAG8jjYpTpwdIj6yAXRIG32vQnDG6ggNXmk7vMEVXtnORbzyzrU49bkbDKwjPo-bZnyKHrW6C_Dsbpyiz4t3n-bvs9OPx8t5dZoZmQuW1Zq0sqA1bYhOD8AESMmNFFAwyWZNTQgVBRetKEROWFMawVouc6pzKaisKZ-it3vvelP30BgYotedWnvbaz8qp636uzLYS3XhtkpSycucJcHLO4F31xsIUfU2GOg6PYDbBEVnIueUFpL8B0oKyRlNC6bo1R413oXgob0_ESXqJgDqJgDqNgAJfvHnHe7R3z-eALoHdraD8R8qdfJlebaX_gIje79s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1807532146</pqid></control><display><type>article</type><title>A Feline‐Specific Anti‐Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease–Associated Pain: A Pilot Proof of Concept Study</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Gruen, M.E. ; Thomson, A.E. ; Griffith, E.H. ; Paradise, H. ; Gearing, D.P. ; Lascelles, B.D.X.</creator><creatorcontrib>Gruen, M.E. ; Thomson, A.E. ; Griffith, E.H. ; Paradise, H. ; Gearing, D.P. ; Lascelles, B.D.X.</creatorcontrib><description>Background
Neutralizing antibodies against nerve growth factor (NGF) are analgesic in rodent models, naturally occurring degenerative joint disease (DJD) pain in dogs, and chronic pain in humans.
Objectives
To evaluate the efficacy of a fully felinized anti‐NGF antibody (NV‐02) for the treatment of DJD pain and mobility impairment in cats.
Animals
Thirty‐four client‐owned cats with DJD‐associated pain and mobility impairment.
Methods
In a placebo‐controlled, pilot, masked clinical study, cats were randomized to a single treatment with NV‐02 (0.4 mg/kg SC [n = 11] or 0.8 mg/kg SC [n = 12]) or placebo (saline, SC [n = 11]). Activity was measured objectively. Additionally, owners completed clinical metrology instruments (client‐specific outcome measures [CSOM] and feline musculoskeletal pain index [FMPI]) on days 0 (screening), 14 (baseline), 35, 56, and 77. A repeated‐measures model was used to evaluate the objective activity data.
Results
NV‐02 significantly increased objectively measured activity overall (P = .017) and at 2 (P = .035), 3 (P = .007), 4 (P = .006), 5 (P = .007), and 6 (P = .017) weeks after treatment. CSOM scores (P = .035) and pain (P = .024) showed a significant effect of treatment 3 weeks after administration. In the treatment group, 83% of the owners correctly identified the treatment administered compared with 45% of owners in the placebo group (P = .013). No treatment‐related adverse effects were identified.
Conclusions
These pilot data demonstrate a 6‐week duration positive analgesic effect of this fully felinized anti‐NGF antibody in cats suffering from DJD‐associated pain.</description><identifier>ISSN: 0891-6640</identifier><identifier>EISSN: 1939-1676</identifier><identifier>DOI: 10.1111/jvim.13972</identifier><identifier>PMID: 27334504</identifier><language>eng</language><publisher>United States: John Wiley and Sons Inc</publisher><subject>adverse effects ; analgesic effect ; analgesics ; Analgesics, Non-Narcotic - therapeutic use ; animal models ; Animals ; Antibodies, Monoclonal - therapeutic use ; Cat Diseases - therapy ; Cats ; Client‐specific outcome measures ; dogs ; Double-Blind Method ; Feline musculoskeletal pain index ; Female ; humans ; Injections, Subcutaneous - veterinary ; Lameness, Animal - therapy ; Male ; metrology ; nerve growth factor ; Nerve Growth Factor - immunology ; neutralizing antibodies ; Osteoarthritis ; Osteoporosis - therapy ; Osteoporosis - veterinary ; pain ; Pain, Intractable - therapy ; Pain, Intractable - veterinary ; Pilot Projects ; placebos ; screening ; SMALL ANIMAL ; Species Specificity ; Treatment Outcome</subject><ispartof>Journal of veterinary internal medicine, 2016-07, Vol.30 (4), p.1138-1148</ispartof><rights>Copyright © 2016 The Authors. .</rights><rights>Copyright © 2016 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5642-ba0f571b1d0a16724e553c54e72528db0014734f474602d9c42f3561a65415b13</citedby><cites>FETCH-LOGICAL-c5642-ba0f571b1d0a16724e553c54e72528db0014734f474602d9c42f3561a65415b13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153962/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153962/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27334504$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gruen, M.E.</creatorcontrib><creatorcontrib>Thomson, A.E.</creatorcontrib><creatorcontrib>Griffith, E.H.</creatorcontrib><creatorcontrib>Paradise, H.</creatorcontrib><creatorcontrib>Gearing, D.P.</creatorcontrib><creatorcontrib>Lascelles, B.D.X.</creatorcontrib><title>A Feline‐Specific Anti‐Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease–Associated Pain: A Pilot Proof of Concept Study</title><title>Journal of veterinary internal medicine</title><addtitle>J Vet Intern Med</addtitle><description>Background
Neutralizing antibodies against nerve growth factor (NGF) are analgesic in rodent models, naturally occurring degenerative joint disease (DJD) pain in dogs, and chronic pain in humans.
Objectives
To evaluate the efficacy of a fully felinized anti‐NGF antibody (NV‐02) for the treatment of DJD pain and mobility impairment in cats.
Animals
Thirty‐four client‐owned cats with DJD‐associated pain and mobility impairment.
Methods
In a placebo‐controlled, pilot, masked clinical study, cats were randomized to a single treatment with NV‐02 (0.4 mg/kg SC [n = 11] or 0.8 mg/kg SC [n = 12]) or placebo (saline, SC [n = 11]). Activity was measured objectively. Additionally, owners completed clinical metrology instruments (client‐specific outcome measures [CSOM] and feline musculoskeletal pain index [FMPI]) on days 0 (screening), 14 (baseline), 35, 56, and 77. A repeated‐measures model was used to evaluate the objective activity data.
Results
NV‐02 significantly increased objectively measured activity overall (P = .017) and at 2 (P = .035), 3 (P = .007), 4 (P = .006), 5 (P = .007), and 6 (P = .017) weeks after treatment. CSOM scores (P = .035) and pain (P = .024) showed a significant effect of treatment 3 weeks after administration. In the treatment group, 83% of the owners correctly identified the treatment administered compared with 45% of owners in the placebo group (P = .013). No treatment‐related adverse effects were identified.
Conclusions
These pilot data demonstrate a 6‐week duration positive analgesic effect of this fully felinized anti‐NGF antibody in cats suffering from DJD‐associated pain.</description><subject>adverse effects</subject><subject>analgesic effect</subject><subject>analgesics</subject><subject>Analgesics, Non-Narcotic - therapeutic use</subject><subject>animal models</subject><subject>Animals</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Cat Diseases - therapy</subject><subject>Cats</subject><subject>Client‐specific outcome measures</subject><subject>dogs</subject><subject>Double-Blind Method</subject><subject>Feline musculoskeletal pain index</subject><subject>Female</subject><subject>humans</subject><subject>Injections, Subcutaneous - veterinary</subject><subject>Lameness, Animal - therapy</subject><subject>Male</subject><subject>metrology</subject><subject>nerve growth factor</subject><subject>Nerve Growth Factor - immunology</subject><subject>neutralizing antibodies</subject><subject>Osteoarthritis</subject><subject>Osteoporosis - therapy</subject><subject>Osteoporosis - veterinary</subject><subject>pain</subject><subject>Pain, Intractable - therapy</subject><subject>Pain, Intractable - veterinary</subject><subject>Pilot Projects</subject><subject>placebos</subject><subject>screening</subject><subject>SMALL ANIMAL</subject><subject>Species Specificity</subject><subject>Treatment Outcome</subject><issn>0891-6640</issn><issn>1939-1676</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNqNkt1qFDEYhoModl098QIkhyJMze_MjgfCsHXrllYXqp6GTOabNmVmsk2yu8yZlyB4Cd6ZV2LarUVPxBAI4Xvy5O9F6DklhzS111db2x9SXhbsAZrQkpcZzYv8IZqQWUmzPBfkAD0J4YoQJqUsHqMDVnAuJBET9KPCC-jsAD-_fjtfg7GtNbgaok3zD-C3gI-928VLvNAmOn9bql0z4mW_9m4LAZ-52nY2jtgOeK5jwDub8CO4gAG8jjYpTpwdIj6yAXRIG32vQnDG6ggNXmk7vMEVXtnORbzyzrU49bkbDKwjPo-bZnyKHrW6C_Dsbpyiz4t3n-bvs9OPx8t5dZoZmQuW1Zq0sqA1bYhOD8AESMmNFFAwyWZNTQgVBRetKEROWFMawVouc6pzKaisKZ-it3vvelP30BgYotedWnvbaz8qp636uzLYS3XhtkpSycucJcHLO4F31xsIUfU2GOg6PYDbBEVnIueUFpL8B0oKyRlNC6bo1R413oXgob0_ESXqJgDqJgDqNgAJfvHnHe7R3z-eALoHdraD8R8qdfJlebaX_gIje79s</recordid><startdate>201607</startdate><enddate>201607</enddate><creator>Gruen, M.E.</creator><creator>Thomson, A.E.</creator><creator>Griffith, E.H.</creator><creator>Paradise, H.</creator><creator>Gearing, D.P.</creator><creator>Lascelles, B.D.X.</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope></search><sort><creationdate>201607</creationdate><title>A Feline‐Specific Anti‐Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease–Associated Pain: A Pilot Proof of Concept Study</title><author>Gruen, M.E. ; Thomson, A.E. ; Griffith, E.H. ; Paradise, H. ; Gearing, D.P. ; Lascelles, B.D.X.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5642-ba0f571b1d0a16724e553c54e72528db0014734f474602d9c42f3561a65415b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>adverse effects</topic><topic>analgesic effect</topic><topic>analgesics</topic><topic>Analgesics, Non-Narcotic - therapeutic use</topic><topic>animal models</topic><topic>Animals</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Cat Diseases - therapy</topic><topic>Cats</topic><topic>Client‐specific outcome measures</topic><topic>dogs</topic><topic>Double-Blind Method</topic><topic>Feline musculoskeletal pain index</topic><topic>Female</topic><topic>humans</topic><topic>Injections, Subcutaneous - veterinary</topic><topic>Lameness, Animal - therapy</topic><topic>Male</topic><topic>metrology</topic><topic>nerve growth factor</topic><topic>Nerve Growth Factor - immunology</topic><topic>neutralizing antibodies</topic><topic>Osteoarthritis</topic><topic>Osteoporosis - therapy</topic><topic>Osteoporosis - veterinary</topic><topic>pain</topic><topic>Pain, Intractable - therapy</topic><topic>Pain, Intractable - veterinary</topic><topic>Pilot Projects</topic><topic>placebos</topic><topic>screening</topic><topic>SMALL ANIMAL</topic><topic>Species Specificity</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gruen, M.E.</creatorcontrib><creatorcontrib>Thomson, A.E.</creatorcontrib><creatorcontrib>Griffith, E.H.</creatorcontrib><creatorcontrib>Paradise, H.</creatorcontrib><creatorcontrib>Gearing, D.P.</creatorcontrib><creatorcontrib>Lascelles, B.D.X.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of veterinary internal medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gruen, M.E.</au><au>Thomson, A.E.</au><au>Griffith, E.H.</au><au>Paradise, H.</au><au>Gearing, D.P.</au><au>Lascelles, B.D.X.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Feline‐Specific Anti‐Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease–Associated Pain: A Pilot Proof of Concept Study</atitle><jtitle>Journal of veterinary internal medicine</jtitle><addtitle>J Vet Intern Med</addtitle><date>2016-07</date><risdate>2016</risdate><volume>30</volume><issue>4</issue><spage>1138</spage><epage>1148</epage><pages>1138-1148</pages><issn>0891-6640</issn><eissn>1939-1676</eissn><abstract>Background
Neutralizing antibodies against nerve growth factor (NGF) are analgesic in rodent models, naturally occurring degenerative joint disease (DJD) pain in dogs, and chronic pain in humans.
Objectives
To evaluate the efficacy of a fully felinized anti‐NGF antibody (NV‐02) for the treatment of DJD pain and mobility impairment in cats.
Animals
Thirty‐four client‐owned cats with DJD‐associated pain and mobility impairment.
Methods
In a placebo‐controlled, pilot, masked clinical study, cats were randomized to a single treatment with NV‐02 (0.4 mg/kg SC [n = 11] or 0.8 mg/kg SC [n = 12]) or placebo (saline, SC [n = 11]). Activity was measured objectively. Additionally, owners completed clinical metrology instruments (client‐specific outcome measures [CSOM] and feline musculoskeletal pain index [FMPI]) on days 0 (screening), 14 (baseline), 35, 56, and 77. A repeated‐measures model was used to evaluate the objective activity data.
Results
NV‐02 significantly increased objectively measured activity overall (P = .017) and at 2 (P = .035), 3 (P = .007), 4 (P = .006), 5 (P = .007), and 6 (P = .017) weeks after treatment. CSOM scores (P = .035) and pain (P = .024) showed a significant effect of treatment 3 weeks after administration. In the treatment group, 83% of the owners correctly identified the treatment administered compared with 45% of owners in the placebo group (P = .013). No treatment‐related adverse effects were identified.
Conclusions
These pilot data demonstrate a 6‐week duration positive analgesic effect of this fully felinized anti‐NGF antibody in cats suffering from DJD‐associated pain.</abstract><cop>United States</cop><pub>John Wiley and Sons Inc</pub><pmid>27334504</pmid><doi>10.1111/jvim.13972</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0891-6640 |
| ispartof | Journal of veterinary internal medicine, 2016-07, Vol.30 (4), p.1138-1148 |
| issn | 0891-6640 1939-1676 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5153962 |
| source | MEDLINE; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | adverse effects analgesic effect analgesics Analgesics, Non-Narcotic - therapeutic use animal models Animals Antibodies, Monoclonal - therapeutic use Cat Diseases - therapy Cats Client‐specific outcome measures dogs Double-Blind Method Feline musculoskeletal pain index Female humans Injections, Subcutaneous - veterinary Lameness, Animal - therapy Male metrology nerve growth factor Nerve Growth Factor - immunology neutralizing antibodies Osteoarthritis Osteoporosis - therapy Osteoporosis - veterinary pain Pain, Intractable - therapy Pain, Intractable - veterinary Pilot Projects placebos screening SMALL ANIMAL Species Specificity Treatment Outcome |
| title | A Feline‐Specific Anti‐Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease–Associated Pain: A Pilot Proof of Concept Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T02%3A19%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Feline%E2%80%90Specific%20Anti%E2%80%90Nerve%20Growth%20Factor%20Antibody%20Improves%20Mobility%20in%20Cats%20with%20Degenerative%20Joint%20Disease%E2%80%93Associated%20Pain:%20A%20Pilot%20Proof%20of%20Concept%20Study&rft.jtitle=Journal%20of%20veterinary%20internal%20medicine&rft.au=Gruen,%20M.E.&rft.date=2016-07&rft.volume=30&rft.issue=4&rft.spage=1138&rft.epage=1148&rft.pages=1138-1148&rft.issn=0891-6640&rft.eissn=1939-1676&rft_id=info:doi/10.1111/jvim.13972&rft_dat=%3Cproquest_pubme%3E1846311750%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1807532146&rft_id=info:pmid/27334504&rfr_iscdi=true |